Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 20/20 | 0.78 |
| ▸ | PIM1 | P11309 | 19/20 | 0.78 |
| ▸ | CDC7 | O00311 | 9/20 | 0.78 |
| ▸ | CSNK2A1 | P68400 | 9/20 | 0.78 |
| ▸ | CSNK2A2 | P19784 | 13/20 | 0.67 |
| ▸ | PIM3 | Q86V86 | 12/20 | 0.67 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.67 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853281 | 0.88 | CSNK2B (1.00) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL1849054 | 0.88 | CSNK2B (1.00) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL1854480 | 0.88 | CSNK2B (1.00) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL1852879 | 0.86 | CSNK2B (0.83) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL12661115 | 0.81 | CSNK2B (0.61) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL12661564 | 0.81 | CSNK2B (0.67) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL1851504 | 0.80 | PIM1 (1.00) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL1848492 | 0.80 | PIM1 (0.69) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL1850376 | 0.79 | CSNK2B (0.72) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 | |
| SCHEMBL1853241 | 0.79 | CSNK2B (0.72) | CSNK2BPIM1CDC7CSNK2A1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | CSNK2B 350/4885PIM1 1977/4885CDC7 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.